SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
Status:
Recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
This study is an open-label, multicenter, phase II single arm trial to evaluate the efficacy
and safety of SBRT in combination with sintilimab and GM-CSF for the treatment of patients
with advanced NSCLC.